Clinical Trials in Sault Ste. Marie, Ontario
3 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled234 locationsNCT06966700
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting
Phase 2Phase 3
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Lung Cancer
Canadian Cancer Trials Group230 enrolled10 locationsNCT04093167
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche450 enrolled210 locationsNCT06790693
Recruiting
Phase 3
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Breast Neoplasm FemaleRadiotherapyCosmetic Outcome
Ontario Clinical Oncology Group (OCOG)910 enrolled27 locationsNCT05417516
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled300 locationsNCT06692738
Recruiting
Phase 3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Hot Flashes
Astellas Pharma Global Development, Inc.540 enrolled117 locationsNCT06440967
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
AstraZeneca878 enrolled282 locationsNCT06627647
Recruiting
Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Breast Cancer
Canadian Cancer Trials Group2,140 enrolled475 locationsNCT03488693
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557